Vertex PharmaceuticalsVRTX
NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.
Key metrics
Market cap
$135B
Price
$547.59
Today
−0.1%
Return YTD
+20.9%
Return 1Y
+37.9%
P/E
30.7
P/S
10.7
P/B
6.7
Data as of 2026-08-25 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Cystic fibrosis
- Pain treatment
- Cell & gene therapy (Casgevy)
Competitors
- Other CF players
- Gene therapy biotechs
Risks
- Concentration in CF franchise
- Pipeline execution
Supply chain
Supplies →
← Suppliers
Same segment: Biotech & innovation
Compare VRTX
See where Vertex Pharmaceuticals sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →